Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis by Gan, Lu et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Rheumatology Faculty Publications Medicine
3-6-2014
Twins discordant for myositis and systemic lupus
erythematosus show markedly enriched
autoantibodies in the affected twin supporting
environmental influences in pathogenesis
Lu Gan
National Institute of Environmental Health Sciences, Bethesda, MD
Terence P. O'Hanlon
National Institute of Environmental Health Sciences, Bethesda, MD
Aaron S. Gordon
National Institutes of Health, Bethesda, MD
Lisa G. Rider
George Washington University
Frederick W. Miller
National Institute of Environmental Health Sciences, Bethesda, MD
See next page for additional authorsFollow this and additional works at: https://hsrc.himmelfarb.gwu.edu/
smhs_medicine_rheum_facpubs
Part of the Rheumatology Commons
This Journal Article is brought to you for free and open access by the Medicine at Health Sciences Research Commons. It has been accepted for
inclusion in Rheumatology Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.
Recommended Citation
Gan, L., O'Hanlon, T.P., Gordon, A.S., Rider, L.G., Miller, F.W. et al. (2014). Twins discordant for myositis and systemic lupus
erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis.
BMC Musculoskeletal Disorders, 15(1):67.
Authors
Lu Gan, Terence P. O'Hanlon, Aaron S. Gordon, Lisa G. Rider, Frederick W. Miller, and Peter D. Burbelo
This journal article is available at Health Sciences Research Commons: https://hsrc.himmelfarb.gwu.edu/
smhs_medicine_rheum_facpubs/21
RESEARCH ARTICLE Open Access
Twins discordant for myositis and systemic lupus
erythematosus show markedly enriched
autoantibodies in the affected twin supporting
environmental influences in pathogenesis
Lu Gan1, Terrance P O’Hanlon1, Aaron S Gordon2, Lisa G Rider1, Frederick W Miller1* and Peter D Burbelo2*
Abstract
Background: Studies of twin pairs discordant for autoimmune conditions provide a unique opportunity to explore
contributing factors triggered by complex gene-environment interactions.
Methods: In this cross-sectional study, thirty-one monozygotic or dizygotic twin pairs discordant for myositis or
systemic lupus erythematosus (SLE), along with matched healthy controls were evaluated for antibodies against a
panel of 21 autoantigens.
Results: Autoantibody profiling revealed that 42% of the affected twins showed significant seropositivity against
autoantigens in the panel. In many of these affected twins, but none of healthy controls, there were high levels of
autoantibodies detected against two or more autoantigens commonly seen in systemic autoimmune diseases
including Ro52, Ro60, RNP-70 K and/or RNP-A. In contrast, only 10% (3/31) of the unaffected twins showed seropositivity
and these immunoreactivities were against single autoantigens not seen in systemic autoimmune diseases. While no
significant differences in autoantibodies were detected between the affected or unaffected twins against thyroid
peroxidase, transglutaminase and several cytokines, 23% of the affected twins with myositis showed autoantibodies
against the gastric ATPase. Analysis of the monozygotic twins separately also revealed a higher frequencies of
autoantibodies in the affected twins compared to the unaffected twins (P = 0.046). Lastly, clinical analysis of both
the affected monozygotic and dizygotic twins revealed that the autoantibody seropositive affected twins had a
greater global disease activity score compared to seronegative affected twins (P = 0.019).
Conclusion: The findings of significantly more autoantibodies in the affected twins with myositis and SLE compared
to the unaffected twins are consistent with potential non-genetic factors playing a role in autoantibody production and
pathogenesis of these autoimmune disorders.
Background
Factors involved in the development of various auto-
immune diseases including type I diabetes (T1D), rheuma-
toid arthritis, myositis, and systemic lupus erythematosus
(SLE) remain poorly defined. Studies of monozygotic twins
with autoimmune conditions including multiple sclerosis,
T1D, rheumatoid arthritis and SLE show a concordance
rate of 20-70%, suggesting that the genetic makeup alone
cannot completely explain the pathogenesis of autoimmun-
ity [1]. Consistent with these findings, genetic linkage stud-
ies have identified a limited number of susceptibility genes
responsible for different autoimmune conditions, many of
which play important roles in immune function [2]. In-
creasing evidence suggests that environmental factors, in-
cluding epigenetic DNA methylation, chemical exposures,
and host-pathogen interactions, may trigger autoimmune
conditions in genetically susceptible individuals [3-5]. Spe-
cific environmental exposures, including pathogens, as well
as with the timing of exposure or infection, are of particu-
lar interest because they may profoundly impact immune
function and may promote autoimmunity [6].
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Systemic autoimmune diseases including systemic
sclerosis, rheumatoid arthritis, SLE and idiopathic in-
flammatory myopathies (IIM) or myositis, are a group of
immune disorders characterized by immune activation,
autoantibody production and tissue destruction involving
multiple organs. Although the target tissues and symp-
toms are markedly different among these diseases, a com-
mon molecular feature is the increased expression of
interferon-regulated genes [7]. For example, gene expres-
sion studies have shown that SLE, Sjögren’s syndrome and
dermatomyositis (DM, a subtype of IIM with characteristic
cutaneous findings) share up-regulated expression of type
1 interferon response genes [8-11]. In some cases, in-
creased interferon-α has been reported in patients with
systemic autoimmune disease, whereby this cytokine likely
drives inflammation in target tissues [12-14].
Autoantibodies are another common feature of these
diseases, which have important clinical and prognostic
utility [15]. A number of autoantibodies such as anti-
DNA, anti-Smith (Sm) and antinuclear antibodies (ANA)
have been selected as classification criteria for SLE [16].
Some autoantibodies are myositis-specific and include
those reactive against aminoacyl-tRNA synthetases, signal
recognition particle, Ku, Mi-2, p155/140, and PM/Scl
[17]. However, autoantibodies against other targets,
such as SSA and SSB, are not disease-specific and can
be detected in patients with most systemic autoimmune
conditions. Besides assisting with clinical diagnosis,
the levels of autoantibodies can correlate with specific
symptoms and disease severity [15]. In some cases, auto-
antibodies have also been detected before clinical symp-
toms, thereby providing insight into the temporal onset
of autoimmune disease [15]. In one seminal study in SLE,
autoantibodies against several targets, including DNA,
SSA, SSB and Sm antigens, were detected before the clin-
ical onset of SLE [18].
However, despite the widespread applications of auto-
antibody testing, only a limited number of studies have
utilized autoantibody profiling to study cohorts of twins
to dissect genetic and environmental factors that may
contribute to systemic autoimmune disorders. In one
small study of seven twin pairs discordant for SLE, 50%
of the affected twins were found to have anti-DNA
antibodies [19]. Other studies have used first degree
relatives of SLE patients instead of twins and have found
higher ANA autoantibody levels in those unaffected,
related subjects than those seen in unrelated, healthy
controls [20,21].
Recently, we have employed a liquid phase immuno-
assay, luciferase immunoprecipitation systems (LIPS),
which utilizes light-emitting recombinant antigens to ef-
ficiently detect antibodies against linear and conform-
ational epitopes associated with a variety of human
autoantigens and infectious agents [22]. Due to the wide
dynamic range of detection and low backgrounds, LIPS
has been highly informative in characterizing autoanti-
body levels in multiple autoimmune conditions, includ-
ing patients with opportunistic infections [23], Sjögren’s
syndrome [24], T1D[25], Stiffman syndrome [26], my-
asthenia gravis [27] and SLE [28]. In T1D, Sjögren’s
syndrome and SLE, LIPS identified unique patient auto-
antibody profiles that potentially associated with disease
subsets [24,25,28]. Here we describe our findings profil-
ing antibodies against a panel of autoantigens in a cohort
of 31 twin pairs discordant for myositis or SLE along with
control subjects.
Methods
Ethics statement and study population
Informed written consent was obtained from all subjects
in accordance with the human experimentation guide-
lines of the Department of Health and Human Services
under multiple IRB-approved protocols, and the studies
were conducted according to the principles expressed in
the Declaration of Helsinki. Under IRB approved proto-
cols at the National Institute of Environmental Health
Sciences, NIH (Bethesda, MD), 31 same-gendered twin
pairs discordant for two different systemic autoimmune
conditions (22 myositis and 9 SLE) were studied as part
of the Twin-Sib study [29,30]. From the 22 affected twins
with myositis, 19 children had dermatomyositis (DM),
two adults had DM and one had polymyositis (PM) con-
tingent on the Bohan and Peter criteria [31,32]. Based
on American College of Rheumatology criteria, there
were five children and four adults with SLE. Both chil-
dren and adults with SLE or IIM were enrolled into the
study within four years of the diagnosis. Patients with
inherited, metabolic, infectious, or other known causes
of disease were excluded. In addition to the twin pairs,
31 unrelated healthy controls that were matched for
age, gender and ethnicity, were enrolled from the NIH
healthy control registry and underwent medical evalu-
ation. These controls were free of trauma, infections,
surgeries and vaccinations for at least eight weeks be-
fore enrollment and had no first-degree family mem-
bers with systemic autoimmune diseases. The physician
performed global assessments of disease activity and
disease damage based on all available information, in-
cluding the patient’s appearance, medical history, physical
examination, laboratory test result, and any medical ther-
apy. The scores of the affected twins were then recorded
by a 0-100 mm visual analogue scale [29,33]. The scales
from 0 to 100 indicate inactive disease/no damage to
most severe disease activity/damage. The available infor-
mation including age, gender, monozygotic/dizygotic sta-
tus, and clinical information including specific diagnosis,
treatment status and other clinical laboratory findings of
the patients are summarized in Table 1.
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LIPS antigens
LIPS tests for many of the autoantigens used in this
study have been previously described and included
targets for systemic autoimmune diseases (Ro52, Ro60,
La, Sm-D3 (Sm), Jo-1, RNP-A, and RNP-70 K), tissue
autoantigens (thyroid peroxidase/TPO), transglutami-
nase/TGM2), the gastric ATPase and cytokines (interleu-
kin-1α/IL-1 α, interferon-α/IFN-α, interferon-ω/ IFN-
ω, interferon-γ/ IFN-γ, interleukin-17/IL-17, GMCSF,
and TNF-β) [23,24,28]. Of note, the SSA LIPS test separ-
ately detects autoantibodies against Ro52 and Ro60
antigens and SSB is directed against the recombinant La
protein. Several new Renilla luciferase fusion protein
constructs were generated for detecting antibodies
against additional known autoantigens essentially as
described using the pREN2 vector [34]. These new
constructs included Ku, Trim-28, ribosomal P0 protein
(P0), and against a C-terminal fragment of PM/Scl.
DNA sequencing was used to confirm the integrity of
all newly described autoantigen constructs. A complete
list of the LIPS antigens used along with their character-
istics and notation about whether they were tested in a
blinded fashion is provided in Table 2.
LIPS testing
LIPS testing was performed as described in a detailed
protocol and video [36]. Briefly, for testing of the cohort,
a master plate of the serum samples was first con-
structed in a deep well master plate by diluting serum
1/10 in buffer A (50 mM Tris, pH 7.5, 100 mM NaCl,
5 mM MgCl2, 1% Triton X-100 and 0.001% bromo-
phenol red). For LIPS analysis, 40 μl of buffer A, 10 μl of
diluted sera from the master plate (1 μl equivalent), and
1 × 107 light units (LU) of Renilla luciferase-antigen
Cos1 cell extract were added to a final volume of 100 μl)
to each well of a standard polypropylene plate. After
incubation for 1 hour at room temperature on a rotary
shaker, the 100 μl antigen-antibody reaction mixture was
transferred to a 96-well filter plate containing 5 μl of a
30% suspension of protein A/G beads and further incu-
bated with shaking. For detecting anti-TGM2 IgA auto-
antibodies, goat anti-human IgA-agarose conjugated
beads (Sigma) were substituted for protein A/G beads.
After 60 minutes of incubation, the filter plates contain-
ing the bead-immobilized antibody-antigen complexes
were washed using a BioMek robotic workstation with a
vacuum manifold. The LU of the filter plates were then
measured in a Berthold LB 960 Centro microplate lumin-
ometer (Berthold Technologies, Bad Wilbad, Germany)
using coelenterazine substrate mix (Promega, Madison,
WI). Additional positive control sera and testing was also
used for validating the diagnostic potential of some of
the antigens. All data represent raw antibody levels with-
out subtracting the buffer blanks. Based on known cut-
offs for most of the autoantigens, seropositivity status
was determined before the codes were broken. For the
new autoantigens generated for this study, cut-off values
were calculated based on the mean plus 3 standard devia-
tions of the healthy controls.
Statistical analysis and heatmap analysis
The antibody levels in the cohort were analyzed using
the GraphPad Prism software (San Diego, CA). Since
this study was exploratory, P values were not corrected
for multiple comparisons and P values less than 0.05 was
deemed as statistically significant. The non-parametric
Mann-Whitney U statistical test was used for comparison
of antibody levels in the different groups. For comparing
the seroprevalence in the different groups, contingency
tables were generated and analyzed using the Fischer’s
exact test for statistical significance.
A heat map was employed for visualization of the
spectrum and intensity of autoantibody responses in the
individual seropositive twin pairs. For construction of
the heatmap, the corresponding twin without autoanti-
bodies was used as a reference group to determine the
fold increase compared to the seropositive twin and was
color-coded according to the key.
Results
Clinical characteristics of the twin cohort
A cohort of 31 disease-discordant twin pairs and 31
matched, healthy controls was utilized to study the preva-
lence of autoantibodies against a panel of defined human
autoantigens. The clinical characteristics of the affected
twins are described in Table 1 including the age, gender,
autoimmune disease diagnosis, mono- and dizygotic twin
Table 1 Clinical Characteristics of 33 Affected Twins
Discordant Affected Twins
Diagnosis 24 dermatomyositis, 6 systemic lupus
erythematosus and 1 polymyositis
Number of Monozygotic Twins 71% (22/31)
Number of Dizygotic Twins 29% (9/31)
Age (mean, ± SD) 14.2 + 2.1 years
Disease Duration (mean, ± SD) 1.69+ 1.5 years
Gender (% Female) 61% (19/31)
Taking Immunosuppressive
Treatmenta
93.5% (29/31)
Global Disease Activity Scoreb
(mean, ± SD)
20.2 + 17.3
Global Disease Damage Scorec
(mean, ± SD)
7.8 + 15.8
aTreatment included prednisone and any immunosuppressive regimen.
bGlobal Disease Activity score was assessed by a physician familiar with the
subject on a 0-100 mm visual analogue scale.
cGlobal Disease Damage score was assessed by a physician familiar with the
subject on a 0-100 mm visual analogue scale.
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status, disease duration and treatment status. Of the 31
twin pairs, 71% were monozygotic and 29% were dizygotic
(Table 1). Clinical diagnoses of the affected twins with
autoimmune disease were DM (67.7%, 21/31), SLE (29.0%,
9/31) and PM (3.2%, 1/31). The average age of the twins in
the cohort was 14.2 ± 2.1 years and most of the affected
twins (93.5%) were being treated with immunosuppressive
agents at the time of testing. A complete list of the avail-
able clinical information in the affected twins with auto-
immune disease is provided (Table 1).
LIPS screening for autoantibodies against the major SLE
autoantigen targets
In total, 21 autoantigens were tested by LIPS (Table 2).
The rationale for examining antibody responses against
many of the autoantigens was their known associa-
tions with autoimmune diseases such as T1D, SLE and
myositis. Initially, 14 different autoantigens were tested
in a blinded fashion. Prior to un-blinding the sample
codes, cut-off values for seropositivity were established
using previously defined cutoff values. Seven additional
autoantigens were tested subsequently (i.e., after the sam-
ple codes were broken) in an effort to identify additional
informative autoantibody responses. Analysis of autoanti-
body production to four of the major SLE autoantigens
revealed seropositive responses in a subset of affected
twins with autoimmune disease. No seropositive re-
sponses were detected in either the unaffected twins or
healthy blood donors (Figure 1 and Table 2). The most
informative autoantibody responses were against Ro52,
one of the two major components comprising the SSA
antigen, in which Ro52 seropositivity was detected in a
total of six affected twins: four with DM and two with
SLE (Figure 1A). Autoantibody levels for the Ro52 sero-
positive subjects showed robust levels that were 10 to
160-fold higher than the unaffected twins and healthy
controls. Autoantibodies against Ro60, RNP-A, and
RNP- 70 K were also detected in 5, 4 and 4 of the affected
twins, respectively, but were not found in any of the
unaffected twins or blood donors (Figure 1 and Table 2).
Table 2 Summary of Seropositivity in the Twins and Healthy Controls
Autoantigena Seropositive
matched control
Seropositive
unaffected
Seropositive
affected
Fischer’s exact testing
unaffected vs. affected
Reference/
comment
N = 31 N = 31 N = 31
Ro52 0 0 6 P = 0.024 [24,28]
Ro60 0 0 5 NS [24,28]
U1-70 K 0 0 5 NS [28]
RNP-A 0 0 5 NS [28]
La 0 0 2 NS [24,28]
Smith 1 0 3 NS [28]
Jo-1 0 0 0 NS [24]
Ku 0 0 2 NS New
PML 0 0 2 NS New
P0 0 0 0 NS New
Trim-28 0 0 0 NS New
TPO 1 1 0 NS [24,25]
TGM2 1 1 0 NS [28]
ATP4B 0 0 5b NS [24,25]
IL-1α 1 0 1 NS [23,35]
IFN-α 0 0 1 NS [23,28,35]
IFN-γ 2 1 1 NS [23,28,35]
IFN-ω 0 0 0 NS [23,28,35]
TNF-β 0 0 1 NS [23,35]
GMCSF 0 0 0 NS [23,35]
IL-17 0 0 0 NS [23,35]
Total 6c 3c 13c P = 0.0078
aAntigens tested in blinded fashion are bolded.
bAll 5 seropositive subjects were from DM affected twins.
CTotal number of seropositive subjects in each group.
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As a group, only the elevated Ro52 autoantibody levels
in the affected twins compared to unaffected twins (or
healthy controls) was statistically significant (Mann
Whitney U test; P = 0.0495).
Some affected twins with autoimmune disease, but none
of the unaffected twins or healthy controls, showed auto-
antibodies against other autoantigens associated with sys-
temic disease including La, PM/Scl and Ku (Figure 2). In
the case of the Sm autoantigen, one of the healthy controls
(1/31) was seropositive, but it was a low autoantibody titer
just above the cut-off value. There were no significant
autoantibodies detected above the cut-off values against
several other potential diagnostic antigens including Jo-1,
PO, or Trim-28 (Table 2). Control assays demonstrating
the presence of high titer autoantibody levels against Jo-1
and P0 autoantigens in other myositis and SLE patients, re-
spectively, with pre-established positive seroreactivities
supported the validity of these tests (data not shown).
The frequency of autoantibody responses was also calcu-
lated for the eight autoantigens (Ro52, Ro60, RNP-70 K,
RNP-A, SM, La, Ku and PML) seen in systemic auto-
immune diseases that showed seropositivity in the cohort.
From this analysis, 32% (7/22) of the twins with myositis
and 44% (4/9) of the twins with SLE demonstrated sero-
positivity (Table 2). Analysis by Fischer’s exact testing
showed only the increased frequency of autoantibodies
against Ro52 in the affected vs. the unaffected twins was
statistically significant (P < 0.05). While 11 of the affected
twins with SLE or myositis demonstrated seropositivity,
none of the healthy twins (0/31) had autoantibodies
against these targets. Evaluation by the Fischer’s exact test
revealed that only the affected (n = 12) and not the un-
affected twins (n = 0) had autoantibodies against the sys-
temic autoantigen targets, and this difference was highly
significant (P < 0.0001). Similarly, as expected, the affected
twins had significantly higher frequencies of autoanti-
bodies against these systemic autoantigen targets com-
pared to the unrelated, healthy controls (P < 0.0001).
Thus, our findings strongly suggest that autoantibodies
against these targets are largely found in the affected twins
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Figure 1 Autoantibodies against lupus–associated autoantigens in the twin cohort. Samples from 93 subjects were evaluated for autoantibodies
against (A.) Ro52, (B.) Ro60, (C.) RNP-70 k and (D.) RNP-A autoantigens. The individual autoantibody levels were plotted on the Y-axis using a log10 scale
and the median autoantibody value in each group is shown by the horizontal line. Only statistically significant P values between the two groups are
shown and were calculated using the Mann-Whitney U test. A pre-determined cut-off value (stippled line) along with seropositive status was assigned
before the identity codes of the blinded samples were broken.
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and not in the unaffected twins or healthy unrelated
controls.
Autoantibodies against the gastric ATPase in the affected
twins with DM
Autoantibody responses in the cohort were also evalu-
ated against several autoantigens associated with other
autoimmune conditions including the TPO autoantigen
present in autoimmune thyroid disease, TGM2 associ-
ated with colon inflammation in celiac disease and the
gastric ATPase associated with autoimmune gastritis
[25]. From LIPS analysis, seropositivity against TPO was
detected in one healthy control and one unaffected twin
(Figure 3A). Similar results were found for TGM2, in
which one blood donor and one unaffected twin was
seropositive (Figure 3B). Interestingly, high levels of auto-
antibodies against the gastric ATPase were only found in
five of the affected twins, but not in healthy twins or con-
trol subjects (Figure 3C). Autoantibody levels for the
anti-ATPase seropositive subjects showed robust levels
that were 10-160 fold higher than the unaffected twins
and healthy controls. Examination of the clinical diagno-
sis of the five anti-gastric ATPase seropositive subjects
revealed that they were all affected twins with DM
thereby showing an overall prevalence of 23.8% in DM.
Anti-gastric ATPase autoantibodies have not been de-
scribed before in myositis and further studies are needed
to assess its clinical usefulness.
Paucity of anti-cytokine autoantibodies in the twin cohort
While cytokines have a well-known association with in-
flammation, anti-viral responses and autoimmunity, less
is known about the presence of autoantibodies against
cytokines in different autoimmune disease cohorts.
Previously, autoantibodies against cytokines have been
identified in several autoimmune conditions including
autoimmune polyendocrinopathy syndrome type I [37] and
SLE [28,38]. From testing the twin cohort for autoanti-
bodies against seven cytokines (IL-1α, IFN-α, IFN-ω, IFN-γ
and IL-17, GMCSF and TNF-β), only a few individuals
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Figure 2 Autoantibodies against additional autoantigen targets in the twin cohort. Samples from 93 subjects were evaluated for
autoantibodies against (A.) Sm, (B.) La, (C.) Ku and (D.) PML antigens. The individual autoantibody levels are plotted on the Y-axis using a log10
scale and the median antibody value in each group is shown by the horizontal line. While a pre-determined cut-off along was seropositive status
was assigned for La and Smith before the sample ID codes were revealed, the cut-off shown for the newly developed PML and Ku autoantigens
were based on differences greater than the mean plus 3 standard deviations.
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were found to have significant seropositivity. In the case
of IFN-α autoantibodies, one healthy control and one
SLE patient were found to be seropositive (Figure 3D and
Table 2). Additional sporadic seropositivity was detected:
a single affected twin with DM had autoantibodies
against TNF- β; IL-1α autoantibodies were found in one
control subject and one affected twin with DM; and IFN-γ
autoantibodies were detected in three healthy controls, a
healthy twin, and one affected twin with DM (Table 2). No
autoantibodies were detected in any of the subjects against
IFN- ω, IL-17 and GMCSF.
Heatmap analysis and clinical correlates of the
seropositive twin pairs
From testing the 21 autoantigen panel, 15 autoantigens
showed significant immunoreactivity with at least one of
the unaffected or affected twins (Table 2). To further
understand individual twin immunoreactivity, a heatmap
analysis was used. Since no twin pair shared seropositiv-
ity against the same autoantigen, a color code was used
to denote the relative-fold elevation in the autoantibody
levels in the seropositive twin above the corresponding
seronegative twin (Figure 4). As shown in the heatmap,
13 affected twins and 3 unaffected twins showed auto-
antibody responses against at least one autoantigen in
the panel. While eleven of the thirteen affected twins
showed autoantibodies against two or more autoanti-
gens, the 3 seropositive, unaffected twins showed auto-
antibodies only against one autoantigen (Figure 4). In
the affected twins, the highest multiple seropositive
subjects had DM and SLE showing immunoreactivity
against 6 and 7 autoantigens, respectively. Importantly,
only the affected twin group had high levels of autoanti-
bodies that were 50 to < 500-fold higher than seronega-
tive twins (Figure 4). Among the monozygotic twins,
31.8% (7/22) were seropositive, while only 4.5% (1/22)
of the unaffected, monozygotic twins was seropositive
(P = 0.046). Additionally, there were a total of 20 sero-
positive responses in the 7 affected monozygotic twins,
but only one autoantibody response was found in one
unaffected, monozygotic twin. In myositis, three of the
22 cases were from adults, but only the one subject with
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Figure 3 High prevalence of anti-gastric autoantibodies in the affected twins with myositis. Samples from 93 subjects were evaluated for
autoantibodies against (A.) TPO, (B.)TGM2, (C.) gastric ATPase and (D.) IFN-α. The individual autoantibody levels are plotted on the Y-axis using a
log10 scale and the median antibody value in each group is shown by the horizontal line. Only the statistically significant P values between the
two groups are shown and were calculated using the Mann-Whitney U test. For these four autoantigens, pre-determined cut-off values along
with the seropositive status were assigned before the sample codes were revealed.
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polymyositis showed significant autoantibodies. Lastly,
inspection of the five ATPase seropositive DM patients
revealed that they were all co-positive for Ro60, as well
as one additional autoantigen, suggesting that the anti-
gastric autoantibodies in myositis reflected existing high
levels of auto-reactivity (Figure 4). Overall, these auto-
antibody profiles highlight the few, single immunore-
activities and low titer autoantibodies found in the
unaffected twins compared to the highly robust auto-
antibody levels against multiple autoantigens seen in the
affected twins. The autoantibody profiles were also ana-
lyzed in relation to the severity of disease in the subjects.
The severity of autoimmune disease as measured by
the physician global disease activity was higher in the
13 seropositive subjects (median score = 22.0) com-
pared to the 18 seronegative subjects (median score = 8.5)
(P = 0.019). Similarly, the global disease damage score was
also significantly increased in the autoantibody positive
patients (P = 0.047).
Discussion
While autoimmune diseases have high morbidity and
mortality, little is known about the cause of most auto-
immune disorders [39]. Here autoantibody profiles were
used to study a cross-sectional cohort of mono-and
dizygotic twins discordant for myositis and SLE. The
overall data provides compelling evidence that autoanti-
bodies selectively segregated in the twins with autoimmune
disease and were not prevalent in the corresponding un-
affected twin or in matched controls. While the presence
of autoantibodies may indicate sustained disease activity in
the affected twins, the reduced seropositivity in the un-
affected twins may indicate a lack of detectable subclinical
disease. Additionally, there were no significant differences
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in autoantibody levels between the unaffected twins and
healthy controls. These findings suggest that there are no
intermediate autoantibody levels in the unaffected twins
between the affected twins and healthy controls.
Although three of the unaffected twins had autoanti-
body responses, the autoantibody levels were low and
directed against three autoantigens, TPO, TGM2 and
IFN-γ, which are not typically associated with systemic
autoimmunity. Autoantibodies against TPO and TGM2
are also common in the general population, while the
low levels of autoantibodies against IFN-γ in one un-
affected twin was unlikely to have neutralizing cytokine
activity. Moreover, the corresponding affected twins in
each case were not found to harbor these three autoanti-
bodies. The presence of autoantibodies in three unaffected
twins may reflect normal, acute inflammatory conditions,
such as those seen in response to infection, or possibly
other immune-mediated abnormalities observed among
relatives of patients with autoimmune conditions. A key
finding in our study was that 31.8% of the monozygotic af-
fected twins were autoantibody seropositive vs. only 4.5%
of the unaffected, monozygotic twins (P = 0.046) suggesting
that the production of autoantibodies likely involves more
than genetic risk factors requiring additional epigenetic or
environmental factors for inducing disease [4,5].
Based on our previous study, approximately 90% of
SLE patients demonstrated autoantibodies against five of
the candidate autoantigens [28]. Surprisingly, we de-
tected only 44% seropositivity for the SLE affected twins
(4/9) and 41% seropositivity for the myositis affected
twins (9/22) against this larger autoantigen panel. The
lower number of seropositive affected twins may have
been due to two features of the cohort. First, the sub-
jects used in the present study were younger (i.e. mean
age of 14.2 years) compared to adults that were used in
the previous study. Children with these autoimmune
manifestations may represent different subsets of pa-
tients and would have had the disease for a relatively
shorter period of time. Secondly, approximately 90% of
the affected twins were receiving treatment, which may
have attenuated autoantibody responses. Another poten-
tial explanation for the observed relative lack of auto-
antibodies is that our autoantigen panel did not include
either anti-DNA or anti-phospholipids antigens for SLE
[40] or other DM-specific autoantigens [41]. A more ex-
tended autoantigen panel including several of these add-
itional autoantigens may provide further insights into
the nature of the disease-discordant twin pair cohort.
Our current findings that affected twins with high auto-
antibody levels had increased disease activity illustrate
the possible clinical usefulness of the LIPS assay ap-
proach in serial analyses.
One novel finding of our study was the detection of
autoantibodies directed against the gastric ATPase in
several myositis patients that were also positive for other
autoantigens. Previous studies have identified autoanti-
bodies against the gastric ATPase in other autoimmune
conditions including autoimmune gastritis [42], Sjögren’s
Syndrome [24], and T1D [25,43]. The finding of gastric
autoantibodies in some myositis patients is perhaps con-
sistent with the gastrointestinal symptoms experienced
in some patients. A variety of organ-specific autoanti-
bodies have recently been described in JDM patients
from Brazil including those against TPO and T1D auto-
antigens [44]. The autoantibodies observed in our cohort
against the gastric ATPase may reflect the B-cell im-
mune dysfunction or epitope spreading in more severe
cases of myositis. It would be of interest to further
examine longitudinal samples from gastric ATPase sero-
positive myositis patients to determine the temporal re-
lationship between seroconversion and myositis disease
onset. Based on recent findings concerning the role of
the intestinal microbiome in autoimmune disease [45],
further studies are needed to explore the possibility
that the gastrointestinal infections might trigger these
autoantibodies.
In contrast to the study by Reichlin et al. [19], we
found little evidence for the presence of autoantibodies
in otherwise healthy unaffected SLE twins. Another
study of ANA autoantibodies in SLE and first-degree rel-
atives (FDR) suggested measurable ANA titers in family
members [20]. In a related SLE study, only a small per-
centage of unaffected family members had autoanti-
bodies against SSA (49.57% with SLE vs. 4.9% FDR) and
DNA (79.1% with SLE vs. 4.58% FDR) [21]. Studies with
adult discordant twins (i.e. average age > 40 years) for
rheumatoid arthritis [46] and Hashimoto’s thyroiditis
[47] have also found autoantibodies in the unaffected
twins. There are some important differences in these
published studies compared to our study. First, our cohort
consisted of primarily myositis patients and a smaller
number of SLE patients. Most importantly, the age of the
subjects from our cross-sectional study was considerably
younger (i.e. mean age of 14.2 years) than other published
studies. If the genetic background is necessary but not suf-
ficient for autoantibody production, the younger twins ex-
amined in our study may have had insufficient time to
develop higher titer autoantibodies. Moreover, our study
used a highly quantitative assay that employed a panel of
autoantigens that focused on specific protein targets. In
this study, we did not examine ANA or anti-DNA auto-
antibodies, which have been characterized more exten-
sively in other studies. It is possible that more subtle
clinical findings like ANA or altered proteomic and gene
expression profiles are present in genetically-related indi-
viduals with and without autoimmune disease [29,30]. For
example, intermediate gene expression profiles have been
observed in unaffected twins compared with affected twins
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and healthy controls [30]. Lastly, it is important to point
out that our study has several limitations, including the
small sample size and combination of adults and children,
resulting from the challenges of identifying and recruiting
qualified twins discordant for IIM and SLE. Additional
studies in larger cohorts will be needed to more com-
pletely assess our findings.
Conclusions
In our cohort of relatively young twins discordant for
myositis or SLE, our results show dramatic differences
in autoantibody profiles between affected and unaffected
twins. The clear difference between the autoantibody
levels of the seropositive patients and the subset of cor-
responding unaffected twins supports the idea that the
developmental onset of autoantibody production is con-
trolled by more than genetic risk factors. Based on the
observed induction of autoantibodies before disease onset
[18], more detailed studies using longitudinal samples from
prospective cohorts may allow potential environmental
triggers to be examined further by concurrent exposure
assays and autoantibody profiling.
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